Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 363

1.

Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.

Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G, Sarrió D, Martín-Guijarro Mdel C, Hernandez L, Palacios J.

Am J Surg Pathol. 2007 Apr;31(4):501-8.

PMID:
17414096
2.

Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO.

J Pathol. 2006 Mar;208(4):495-506.

PMID:
16429394
3.

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.

Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benítez J.

Breast Cancer Res Treat. 2005 Mar;90(1):5-14.

PMID:
15770521
4.

P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.

Paredes J, Lopes N, Milanezi F, Schmitt FC.

Virchows Arch. 2007 Jan;450(1):73-80. Epub 2006 Nov 23.

PMID:
17123107
5.
6.

Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.

González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ.

Hum Pathol. 2009 Sep;40(9):1224-33. doi: 10.1016/j.humpath.2008.12.022. Epub 2009 May 12.

PMID:
19439346
7.

Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.

Shin BK, Lee Y, Lee JB, Kim HK, Lee JB, Cho SJ, Kim A.

Oncol Rep. 2008 Mar;19(3):617-25.

PMID:
18288392
8.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
9.

p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas.

Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F.

Virchows Arch. 2005 Oct;447(4):688-94. Epub 2005 Oct 19.

PMID:
16012853
10.
11.

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J.

Breast Cancer Res Treat. 2006 Sep;99(1):85-90. Epub 2006 Mar 16.

PMID:
16541313
12.

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

PMID:
19390427
13.

The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

Fadare O, Wang SA, Hileeto D.

Hum Pathol. 2008 Mar;39(3):331-6. doi: 10.1016/j.humpath.2007.07.014.

PMID:
18261623
14.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.

15.

Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.

Arnes JB, Bégin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD, Akslen LA.

J Clin Pathol. 2009 Feb;62(2):139-46. doi: 10.1136/jcp.2008.056291. Epub 2008 Aug 4.

PMID:
18682421
16.

Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.

Williams DJ, Cohen C, To TV, Page AJ, Lawson D, Sussman ZM, Nassar A.

Hum Pathol. 2009 Aug;40(8):1176-81. doi: 10.1016/j.humpath.2009.01.003. Epub 2009 Apr 14.

PMID:
19368951
17.

Prognostic markers in triple-negative breast cancer.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.

Cancer. 2007 Jan 1;109(1):25-32.

18.

Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.

Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J.

Mod Pathol. 2007 Apr;20(4):474-81. Epub 2007 Mar 2.

19.

Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.

Marchiò C, Iravani M, Natrajan R, Lambros MB, Geyer FC, Savage K, Parry S, Tamber N, Fenwick K, Mackay A, Schmitt FC, Bussolati G, Ellis I, Ashworth A, Sapino A, Reis-Filho JS.

J Pathol. 2009 Jul;218(3):301-15. doi: 10.1002/path.2572.

PMID:
19479727
20.

Identification of a basal-like subtype of breast ductal carcinoma in situ.

Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.

Hum Pathol. 2007 Feb;38(2):197-204.

PMID:
17234468

Supplemental Content

Support Center